Memantin Aurobindo

Memantine hydrochloride, the active ingredient in Memantin Aurobindo, is an NMDA receptor antagonist presented as a tablet (strength not specified) for oral use. It is indicated for the symptomatic treatment of Alzheimer’s disease in adult patients, helping to improve cognition and daily functioning.

GNH USA supplies Memantin Aurobindo as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The company adheres to stringent quality standards and provides reliable logistics for global distribution. All batches are manufactured under GMP conditions and undergo rigorous testing before release.

Memantin Aurobindo, an NMDA receptor antagonist, is used in the management of Alzheimer’s disease.

Alzheimer’s disease (mild to moderate): improves cognitive function and daily activities. Alzheimer’s disease (moderate to severe): helps maintain functional abilities. Behavioral disturbances in Alzheimer’s disease: may reduce agitation and aggression.

Memantin Aurobindo may be associated with a range of adverse reactions, which are categorized by frequency and severity.

Common Side Effects: - Dizziness - Headache - Constipation - Confusion - Fatigue - Nausea

Serious or Rare Side Effects: - Severe allergic reaction (anaphylaxis) - Stevens‑Johnson syndrome - Seizures - Hallucinations - Cardiac arrhythmia - Hepatic injury

When prescribing Memantin Aurobindo, clinicians should consider several safety measures.

Dose titration: start with low dose and increase gradually as tolerated. Renal impairment: adjust dose in patients with reduced kidney function. History of seizures: monitor closely as drug may lower seizure threshold. Concurrent use with NMDA agonists: avoid due to antagonistic effect. Pregnancy and lactation: use only if benefit outweighs risk (category unknown). Store at ambient temperature: keep in original container, protect from moisture and light.

Memantin Aurobindo can interact with other medicines; interactions are grouped by clinical relevance.

Major Interactions (Avoid): - Amantadine: additive NMDA antagonism may increase toxicity. - Ketamine: combined NMDA blockade may cause excessive CNS depression. - High‑dose zinc supplements: may reduce absorption.

Moderate Interactions (Monitor Closely): - Anticholinesterases (e.g., donepezil): may blunt therapeutic effect. - Diuretics: may increase risk of dehydration and dizziness. - CNS depressants (e.g., benzodiazepines): may enhance sedation.